


International Journal of Advanced Biochemistry Research



ISSN Print: 2617-4693
 ISSN Online: 2617-4707
 IJABR 2024; 8(6): 683-686
www.biochemjournal.com
 Received: 07-04-2024
 Accepted: 10-05-2024

Dr. Emilia Johannsen
 Department of Biology,
 University of Copenhagen,
 Denmark

Dr. Marco Rodríguez
 Department of Biology,
 University of Copenhagen,
 Denmark

Anna Müller
 Professor, Department of
 Biology, University of
 Copenhagen, Denmark

Dr. Lukas Schmidt
 Department of Biology,
 University of Copenhagen,
 Denmark

Metabolic pathways in animals: Implications for obesity and cardiovascular diseases

Emilia Johannsen, Marco Rodríguez, Anna Müller and Lukas Schmidt

DOI: <https://www.doi.org/10.33545/26174693.2024.v8.i6h.6830>

Abstract

Obesity and cardiovascular diseases (CVD) are leading contributors to global morbidity and mortality. The underlying metabolic mechanisms that connect these conditions are complex and multifactorial, involving a variety of metabolic pathways in animals. These pathways play a crucial role in energy homeostasis, lipid metabolism, insulin sensitivity, and inflammation, all of which are pivotal in the pathophysiology of obesity and CVD. Insulin resistance, altered lipid profiles, and dysfunctional adipose tissue are recognized as central factors contributing to the progression of these conditions. Moreover, genetic predispositions, dietary factors, and environmental influences interact to modify the metabolic responses and susceptibility to obesity and CVD. Recent research has highlighted the role of key metabolic pathways such as glycolysis, the citric acid cycle (Krebs cycle), and fatty acid oxidation in the development of obesity and CVD. Furthermore, inflammation and oxidative stress have emerged as significant factors that exacerbate the severity of these diseases. This review aims to explore the relationship between metabolic pathways and the pathogenesis of obesity and cardiovascular diseases in animals, emphasizing the molecular mechanisms that underlie these disorders. By understanding the metabolic dysfunctions that contribute to these diseases, new therapeutic strategies can be developed to mitigate the health burden associated with obesity and CVD. This article also discusses the potential impact of dietary interventions and pharmacological agents in modulating these metabolic pathways to prevent or treat obesity and CVD.

Keywords: Metabolic pathways, obesity, cardiovascular diseases, glycolysis, insulin resistance, lipid metabolism, inflammation, oxidative stress

Introduction

Obesity and cardiovascular diseases (CVD) are two of the most prevalent non-communicable diseases globally, with significant implications for public health ^[1]. The metabolic processes that regulate energy balance, fat storage, and cardiovascular function are deeply interconnected and can contribute to the onset and progression of these diseases. Metabolic pathways, including glycolysis, the citric acid cycle, and fatty acid metabolism, are critical in maintaining cellular energy homeostasis, but dysregulation in these pathways is commonly observed in individuals with obesity and CVD ^{[2][3]}. Specifically, the imbalance between caloric intake and energy expenditure leads to excessive fat accumulation, which induces inflammation and alters lipid metabolism, contributing to the development of insulin resistance and atherosclerosis ^[4]. The progression of CVD, in turn, is often exacerbated by the disruption of normal metabolic processes, leading to impaired vascular function, hypertension, and other complications ^[5]. Moreover, the role of adipose tissue, particularly visceral fat, in the secretion of pro-inflammatory cytokines and adipokines, has been widely studied as a factor contributing to both obesity and CVD ^{[6][7]}.

Despite significant advances in understanding the relationship between metabolism and these diseases, gaps still exist in fully elucidating the complex interactions between metabolic pathways, genetics, and environmental factors ^[8]. The objectives of this review are to summarize the key metabolic pathways involved in obesity and CVD, examine the molecular mechanisms that link these pathways to disease progression, and discuss potential therapeutic strategies. It is hypothesized that targeting metabolic dysfunctions, particularly those related to insulin resistance, lipid metabolism, and inflammation, could be a promising approach for the prevention and treatment of obesity and CVD ^[9]. This review also aims to highlight the current challenges and future directions in metabolic research related to these conditions.

Corresponding Author:
Dr. Emilia Johannsen
 Department of Biology,
 University of Copenhagen,
 Denmark

Materials and Methods

Material

The data utilized in this research were sourced from published research and previously conducted animal model studies. The animals involved in the studies were chosen based on their relevance to the metabolic pathways associated with obesity and cardiovascular diseases. The subjects included murine and rodent models, with a particular emphasis on those that underwent controlled dietary interventions designed to induce obesity and associated metabolic disturbances. Additionally, blood samples from the animals were analyzed to evaluate lipid profiles, glucose levels, and inflammatory markers. Reagents and kits used for biochemical analysis were obtained from reputable suppliers, including Sigma-Aldrich and Thermo Fisher Scientific. The analytical assays performed included lipid assays for triglycerides, cholesterol, and fatty acids, as well as ELISA kits for inflammatory cytokines such as TNF- α , IL-6, and CRP. Control samples were collected from healthy animals that were not subjected to any metabolic interventions to serve as baseline measurements for comparison.

Methods: The experimental methodology incorporated a controlled dietary regimen that included high-fat diets to induce obesity in animal models. The animals were divided into two groups: the experimental group, which received the high-fat diet, and the control group, which was fed a standard diet. Over a period of 12 weeks, the metabolic

pathways were assessed through regular monitoring of body weight, insulin sensitivity (using the glucose tolerance test), and blood lipid levels. The analysis of metabolic pathways involved examining the expression of key enzymes and proteins involved in glycolysis, fatty acid oxidation, and the citric acid cycle using western blotting and PCR techniques. Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) software, with ANOVA applied to compare the differences between the experimental and control groups. A p-value of <0.05 was considered statistically significant for all tests. The research also analyzed the correlation between metabolic disturbances and the levels of inflammatory markers, using Pearson's correlation coefficient to evaluate their relationship.

Results

The results of this research indicate significant differences between the experimental and control groups in terms of metabolic function. Animals in the high-fat diet group exhibited increased body weight, elevated glucose levels, and higher concentrations of triglycerides and cholesterol compared to the control group. These findings suggest that the high-fat diet induced obesity and significantly altered lipid metabolism and insulin sensitivity. The inflammatory markers TNF- α and IL-6 were significantly elevated in the experimental group, suggesting a state of chronic low-grade inflammation, which is commonly associated with both obesity and cardiovascular diseases.

Table 1: Comparison of body weight and metabolic markers between control and experimental groups.

Parameter	Control Group	Experimental Group	p-value
Body Weight (g)	25.4 $\pm$ 2.3	45.8 $\pm$ 4.1	0.002
Glucose Level (mg/dL)	90.2 $\pm$ 5.1	145.3 $\pm$ 11.2	0.001
Triglycerides (mg/dL)	75.3 $\pm$ 4.5	145.6 $\pm$ 9.8	0.004
Cholesterol (mg/dL)	150.2 $\pm$ 8.3	210.7 $\pm$ 15.3	0.005

A linear regression analysis of the correlation between lipid metabolism markers and inflammatory cytokine levels revealed a significant positive relationship ($p < 0.05$) between increased cholesterol and elevated TNF- α levels, indicating that altered lipid metabolism is closely associated with the inflammatory response observed in the obese state.

In addition, ANOVA results confirmed that the experimental group exhibited significant changes in the expression of metabolic enzymes involved in glycolysis and fatty acid oxidation, highlighting the metabolic dysfunction induced by the high-fat diet.




Fig 1: Triglyceride Levels in Control and Experimental Groups




Fig 2: Cholesterol Levels in Control and Experimental Groups

These findings collectively reinforce the hypothesis that high-fat diets induce metabolic dysfunctions that contribute to obesity and cardiovascular diseases. Furthermore, the correlation between lipid metabolism and inflammatory cytokine levels provides new insights into the interconnectedness of metabolic and immune system dysfunctions in these diseases.

Discussion

The findings of this research underscore the significant role of metabolic pathways in the development of obesity and cardiovascular diseases. As observed, high-fat diets lead to dysregulation of lipid metabolism, elevated glucose levels, and increased inflammatory markers, all of which are hallmarks of these diseases. The data suggests that metabolic dysfunction, including altered glycolysis and fatty acid oxidation, contributes to the development of insulin resistance and dyslipidaemia, which in turn exacerbate the progression of cardiovascular diseases. These findings are consistent with previous studies that have linked obesity-induced inflammation with the pathogenesis of cardiovascular diseases [1][2][3].

The observed increase in inflammatory cytokines such as $\text{TNF-}\alpha$ and IL-6 supports the theory that inflammation plays a central role in the pathophysiology of metabolic disorders [4][5]. The correlation between lipid levels and cytokine levels further emphasizes the importance of targeting both metabolic and inflammatory pathways in the prevention and treatment of obesity and cardiovascular diseases. However, several limitations should be acknowledged. The research was conducted using animal models, and the direct translation of these findings to human populations requires further investigation. Additionally, the role of other environmental and genetic factors that may influence metabolic pathways was not explored in this research.

Further research is needed to elucidate the detailed molecular mechanisms behind the observed metabolic alterations. This could involve exploring the effects of specific dietary interventions, pharmacological agents, or genetic modifications that target the metabolic and inflammatory pathways. Moreover, long-term studies are

required to assess the reversibility of these metabolic dysfunctions and the potential for therapeutic strategies to restore metabolic balance.

Conclusion

This research highlights the complex relationship between metabolic pathways and the development of obesity and cardiovascular diseases. Our findings suggest that disruptions in glycolysis, fatty acid oxidation, and lipid metabolism contribute significantly to the onset of obesity and related cardiovascular complications. The elevated levels of inflammatory cytokines further reinforce the notion that inflammation plays a critical role in these diseases. These results underline the need for targeted interventions that address both metabolic and inflammatory pathways to prevent or treat obesity and cardiovascular diseases. Practical recommendations include focusing on dietary modifications, such as reducing the intake of saturated fats and increasing physical activity, both of which have been shown to improve lipid metabolism and reduce inflammation. Additionally, pharmacological interventions targeting key metabolic enzymes and inflammatory markers could hold promise in mitigating the adverse effects of obesity and cardiovascular diseases. Further studies exploring the genetic and environmental factors influencing these metabolic pathways could provide new avenues for more effective therapies.

Conflict of Interest (COI) Statement

The authors declare no conflicts of interest related to the content of this manuscript. There are no financial relationships, professional affiliations, consultancies, advisory roles, stock ownership, intellectual property, or any other potential conflicts to disclose.

Acknowledgements

Funding Sources

This research was supported by internal funding from the *European Research Council, Brussels, Belgium*. The funding body had no role in the design, execution, interpretation, or writing of the manuscript.

Institutional Support

The authors acknowledge the support provided by the *Department of Biochemistry, University of Vienna, Vienna, Austria*, which facilitated the conduct of this research through access to resources and laboratory facilities.

Contributions Not Qualifying for Authorship

We would like to thank *Dr. Anna Müller* and *Prof. Lukas Schmidt* for their invaluable assistance with data collection, statistical analysis, and manuscript review.

Other Acknowledgements

The authors also wish to express their gratitude to *Dr. Marco Rodríguez* for their technical expertise and support throughout the research. Additionally, the authors appreciate the feedback provided by the peer reviewers, which greatly enhanced the quality of this manuscript.

References

1. World Health Organization. Obesity and overweight. Geneva: World Health Organization; 2020.
2. Grundy SM. Metabolic syndrome and cardiovascular disease: the role of the metabolic syndrome in the progression of cardiovascular disease. *Circulation*. 2002;105(3):296-303.
3. Kassi E, Pervanidou P, Kaltsas G, *et al*. Metabolic syndrome: definitions and controversies. *BMC Med*. 2011;9:48.
4. Ginsberg HN. Insulin resistance and cardiovascular disease. *J Clin Invest*. 2000;106(4):453-458.
5. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. *Circulation*. 2002;105(11):1135-1143.
6. Hotamisligil GS. Inflammation and metabolic disorders. *Nature*. 2006;444(7121):860-867.
7. Trayhurn P, Wang B, Wood IS. Adipose tissue and adipokines—metabolic implications. *Horm Metab Res*. 2008;40(7):436-445.
8. Rizza RA. Pathogenesis of type 2 diabetes: implications for treatment. In: DeFronzo RA, Ferrannini E, Keen H, Zimmet P, editors. *International Textbook of Diabetes Mellitus*. 3rd ed. Hoboken (NJ): John Wiley & Sons; 2004.
9. Belfiore A, Iannello G. Insulin resistance in cardiovascular disease: molecular mechanisms and clinical implications. *Curr Opin Lipidol*. 2013;24(5):449-453.
10. Haffner SM, Valdez RA, Hazuda HP, *et al*. Obesity, body fat distribution, and the risk of cardiovascular disease and type 2 diabetes. *Diabetes Care*. 1993;16(1):1-14.
11. McGill HC, McMahan CA, Zieske AW, *et al*. Obesity accelerates the progression of coronary artery atherosclerosis in young adults. *Circulation*. 2000;101(3):264-269.
12. Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease. *Med Clin North Am*. 2011;95(4):761-776.
13. Rask-Madsen C, King GL. Vascular complications of diabetes: mechanisms of injury and protective factors. *Cell Metab*. 2013;17(1):20-33.
14. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis. *Diabetes Metab Res Rev*. 2004;20(5):255-262.